A number of other brokerages have also weighed in on CELG. BMO Capital Markets raised their price objective on shares of Celgene from $148.00 to $155.00 and gave the company an outperform rating in a report on Friday, November 17th. Oppenheimer restated a buy rating and issued a $170.00 price objective on shares of Celgene in a report on Friday, October 20th. Vetr upgraded shares of Celgene from a buy rating to a strong-buy rating and set a $144.39 price objective on the stock in a report on Monday, October 23rd. Cann restated a buy rating on shares of Celgene in a report on Thursday, October 26th. Finally, Morgan Stanley upgraded shares of Celgene from an underweight rating to an equal weight rating in a research note on Friday, October 27th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and nineteen have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average price target of $131.18.
Shares of Celgene (NASDAQ CELG) traded down $2.68 during mid-day trading on Monday, reaching $102.14. 7,928,973 shares of the company’s stock traded hands, compared to its average volume of 6,290,000. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. Celgene has a 52 week low of $94.55 and a 52 week high of $147.17. The stock has a market cap of $80,440.00, a PE ratio of 24.09, a PEG ratio of 0.68 and a beta of 1.77.
A number of hedge funds and other institutional investors have recently bought and sold shares of CELG. Janus Henderson Group PLC boosted its holdings in shares of Celgene by 4,290.5% in the second quarter. Janus Henderson Group PLC now owns 8,408,961 shares of the biopharmaceutical company’s stock valued at $1,092,071,000 after acquiring an additional 8,217,433 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Celgene by 5.7% in the second quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock valued at $7,366,919,000 after acquiring an additional 3,084,227 shares in the last quarter. Oaktop Capital Management II L.P. purchased a new stake in shares of Celgene in the second quarter valued at about $271,605,000. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Celgene by 1,489.2% in the second quarter. Arrowstreet Capital Limited Partnership now owns 1,907,052 shares of the biopharmaceutical company’s stock valued at $247,669,000 after acquiring an additional 1,787,052 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Celgene by 3.1% in the second quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock valued at $6,951,579,000 after acquiring an additional 1,610,056 shares in the last quarter. Institutional investors own 79.85% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was first published by BBNS and is the property of of BBNS. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://baseballnewssource.com/markets/celgene-celg-pt-set-at-127-00-by-suntrust-banks/1823206.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.